Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer?

Expert Opinion on Therapeutic Targets

Volumn 16, Issue SUPPL. 1, 2012, Pages

  Glck, Stefan ^a   Yip, Adrian Yun San ^b   Ng, Elizabeth Lam Yan ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Organisation for Oncology and Translational Research   (Hong Kong)

Author keywords

Early breast cancer; Microarrays; Microscope; Molecular tests

Indexed keywords

ANTIESTROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER THERAPY; CLINICAL DECISION MAKING; CLINICAL PRACTICE; DIAGNOSTIC PROCEDURE; GENE EXPRESSION; HUMAN; MICROARRAY ANALYSIS; MICROSCOPE; PREDICTIVE VALUE; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT PLANNING;

BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MICROSCOPY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN;

EID: 84857560540     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.655725     Document Type: Review

References (32)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717
2. Davies C, Godwin J, Gray R, et al. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378:771-84
3. Gluck S, Mamounas T. Improving outcomes in early-stage breast cancer. Oncology 2010;24:S1-15
4. Nkoy FL, Hammond ME, Rees W, et al. Variable specimen handling affects hormone receptor test results in women with breast cancer: a large multihospital retrospective study. Arch Pathol Lab Med 2010;134:606-12
5. Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007;25:3846-52 (Pubitemid 47477259)
6. Welsh AW, Moeder CB, Kumar S, et al. Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J Clin Oncol 2011;29:2978-84
7. Reddy JC, Reimann JD, Anderson SM, et al. Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clin Breast Cancer 2006;7:153-7 (Pubitemid 44044012)
8. Gluck S, Ross JS, Royce M, et al. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. Breast Cancer Res Treat 2011; published online 4 March 2011; doi: 10.1007/s10549-011-1412-7.
9. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736-47
10. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26 (Pubitemid 40051905)
11. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6 (Pubitemid 34130608)
12. Bartlett JM, Thomas J, Ross DT, et al. Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. Breast Cancer Res 2010;12:R47
13. Nielsen TO, Parker JS, Leung S, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010;16:5222-32
14. van Zitteren M, van der Net JB, Kundu S, et al. Genome-based prediction of breast cancer risk in the general population: a modeling study based on meta-analyses of genetic associations. Cancer Epidemiol Biomarkers Prev 2011;20:9-22
15. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-34 (Pubitemid 46622311)
16. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55-65
17. Owusu C, Buist DS, Field TS, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 2008;26:549-55 (Pubitemid 351264347)
18. The TAILORx Breast Cancer Trial. National Cancer Institute. Bethesda, MD: National Institute of Health, 2005. Available from: www.cancer.gov/ clinicaltrials/noteworthy-trials/tailorx [Last accessed 29 August 2011]
19. Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901-6
20. Albain KS, Barlow WE, Ravdin PM, et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:2055-63
21. Mamounas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 2010;28:1677-83
22. Ioannidis JPA. Is molecular profiling ready for use in clinical decision making? Oncologist 2007;12:301-11 (Pubitemid 46556796)
23. Knauer M, Rutgers EJ, Mook S, et al. Evaluation of the 70-gene prognosis MammaPrint signature for the prediction of prognosis of breast cancer independently from histologic grade. J Clin Oncol 2010;28:abstract 561
24. Knauer M, Mook S, Rutgers EJ, et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2010;120:655-61
25. Straver ME, Glas AM, Hannemann J, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2010;119:551-8
26. Rutgers E, Piccart-Gebhart MJ, Bogaerts J, et al. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. Eur J Cancer 2011; published online 3 November 2011; doi: 10.1016/j.ejca.2011.09.016
27. Hall PS, McCabe C, Stein RC, et al. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. J Natl Cancer Inst 2011;published online 2 December 2011; doi: 10.1093/jnci/djr484
28. Kondo M, Hoshi SL, Yamanaka T, et al. Economic evaluation of the 21-gene signature (Oncotype DX ) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03). Breast Cancer Res Treat 2011;127:739-49
29. Chen E, Tong KB, Malin JL. Cost-effectiveness of 70-gene MammaPrint signature in node-negative breast cancer. Am J Manag Care 2010;16:e333-42
30. Retel VP, Joore MA, Knauer M, et al. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. Eur J Cancer 2010;46:1382-91
31. Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 2011;29:4273-8
32. Kaufmann M, Pusztai L; Biedenkopf Expert Panel Members. Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel. Cancer 2011;117:1575-82.